Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition.


Journal

NPJ genomic medicine
ISSN: 2056-7944
Titre abrégé: NPJ Genom Med
Pays: England
ID NLM: 101685193

Informations de publication

Date de publication:
17 Mar 2021
Historique:
received: 16 09 2020
accepted: 25 01 2021
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 19 3 2021
Statut: epublish

Résumé

Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of NSSM are not well characterized. Here, we report a case of a patient with relapsed and refractory NSMM with brain metastasis harboring a TFG-ALK fusion showing a dramatic and durable (over two years) response to commercially available anaplastic lymphoma kinase (ALK) inhibitors. The case emphasizes the beneficial role of molecular profiling in this target-poor disease.

Identifiants

pubmed: 33731690
doi: 10.1038/s41525-021-00186-9
pii: 10.1038/s41525-021-00186-9
pmc: PMC7969947
doi:

Types de publication

Journal Article

Langues

eng

Pagination

23

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Pathol Res Pract. 2011 Sep 15;207(9):587-91
pubmed: 21855232
Blood. 2012 Aug 2;120(5):1060-6
pubmed: 22529291
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000
pubmed: 26286987
Blood. 1999 Nov 1;94(9):3265-8
pubmed: 10556217
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Rev Cancer. 2013 Nov;13(11):772-87
pubmed: 24132104
Transl Lung Cancer Res. 2015 Dec;4(6):797-800
pubmed: 26798590
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366041
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
J Leukoc Biol. 2004 Sep;76(3):528-36
pubmed: 15155772
Nat Genet. 2015 Oct;47(10):1194-9
pubmed: 26343386
JAMA Dermatol. 2016 Mar;152(3):323-7
pubmed: 26677003
Front Genet. 2019 May 08;10:424
pubmed: 31139207
Oncologist. 2017 Dec;22(12):1444-1450
pubmed: 29079636
Oncotarget. 2018 Apr 10;9(27):19223-19232
pubmed: 29721196
Leukemia. 2018 Nov;32(11):2435-2444
pubmed: 29654269

Auteurs

Ashiq Masood (A)

Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, 60612, USA. Ashiq_Masood@rush.edu.
Rush Precision Oncology Program, Rush University Medical Center, Chicago, IL, 60612, USA. Ashiq_Masood@rush.edu.

Trevor Christ (T)

Rush Precision Oncology Program, Rush University Medical Center, Chicago, IL, 60612, USA.
Department of Pharmacy, Rush University Medical Center, Chicago, IL, 60612, USA.

Samia Asif (S)

Department of Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, 12 64108, USA.

Priya Rajakumar (P)

Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, 60612, USA.

Beth A Gustafson (BA)

Precision Oncology Program, St Luke's Cancer Institute, Kansas City, MO, 64111, USA.

Leyla O Shune (LO)

Department of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas, KS, 66205, USA.

Ameen Salahudeen (A)

Tempus Labs, Inc, Chicago, IL, USA.

Drew Nedvad (D)

MAWD Pathology Group, North Kansas City, MO, 64116, USA.

Suparna Nanua (S)

Department of Pathology, St Luke's Cancer institute, Kansas City, MO, 64111, USA.

Agne Paner (A)

Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, 60612, USA.

Timothy M Kuzel (TM)

Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, 60612, USA.

Mia Levy (M)

Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, 60612, USA.

Janakiraman Subramanian (J)

Precision Oncology Program, St Luke's Cancer Institute, Kansas City, MO, 64111, USA.
Division of Oncology, Saint Luke's Cancer Institute, University of Missouri School of Medicine, Kansas City, MO, 64111, USA.

Shahzad Raza (S)

Division of Oncology, Saint Luke's Cancer Institute, University of Missouri School of Medicine, Kansas City, MO, 64111, USA.

Classifications MeSH